Advances in interleukin 2 receptor targeted treatment

Annals of the Rheumatic Diseases

Volumn 59, Issue SUPPL. 1, 2000, Pages

  Morris, J C ^a   Waldmann, T A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIBODY CONJUGATE; CORTICOSTEROID; DENILEUKIN DIFTITOX; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; IMMUNOTOXIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY LO TACT 1; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIBODY SPECIFICITY; AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; FEVER; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; HYPOTENSION; IMMUNOGENICITY; KIDNEY TRANSPLANTATION; LIVER TOXICITY; LIVER TRANSPLANTATION; LYMPHATIC SYSTEM TUMOR; NONHUMAN; PANCYTOPENIA; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BINDING; RHEUMATOID ARTHRITIS; T CELL LEUKEMIA; T CELL LYMPHOMA; T LYMPHOCYTE ACTIVATION; UVEITIS; VOMITING;

ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; GRAFT REJECTION; HUMANS; NEOPLASMS; RECEPTORS, INTERLEUKIN-2;

EID: 0033764673     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (85)

1. Selective in vitro growth of T-lymphocytes from human bone marrow
2. Long-term culture of tumour-specific cytotoxic T cells
3. Structure and expression of a cloned cDNA for human interleukin-2
4. Interleukin-2: Inception, impact and implications
5. The interleukin-2 receptor
6. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T-cells
7. Molecular cloning and expression of cDNAs for the human interleukin-2 receptor
8. Demonstartion of a new (non-Tac) peptide that binds interleukin-2: A potential participant in a multichain interleukin-2 complex
9. Cloning of the γ-chain of the human IL-2 receptor
10. Novel interleukin-2 receptor subunit detected by cross-linking under high affinity conditions
11. Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2
12. Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells
13. The use of antibodies against the IL-2 receptor in transplantation
14. T-cell growth factor receptors
15. The structure, function, and expression of interleukin-2 receptors on normal and malignant T-cells
16. Structure-function relationships for the IL-2 receptor system
17. Biophysical characterization of a recombinant soluble interleukin-2 receptor (Tac)
18. Metabolism of Tac (IL-2Rα): Physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding
19. In vivo administration of purified human interleukin-2 to patients with cancer: Development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin administration
20. A monoclonal antibody 7G7/B6, binds to an epitope on the human interleukin-2 (IL-2) receptor that is distinct from that recognized by IL-2 or anti-Tac
21. Characterization of the interleukin-2 receptor β-chain using three distinct monoclonal antibodies
22. Monoclonal antibodies defining distinct epitopes of the human IL-2 receptor β-chain and their differential effects on responses
23. Humanized Mikβ1, a humanized antibody to the IL-2 receptor β-chain that acts synergistically with humanized anti-Tac
24. Mouse/human chimeric monoclonal antibodies in man: Kinetics and immune response
25. A humanized antibody that binds to the interleukin-2 receptor
26. Anti-Tac-H, a humanized antibody to the interleukin-2 receptor with new features for immunotherapy in malignant and immune disorders
27. The soluble interleukin-2 receptor in rheumatic disease
28. Serum levels of interleukin-2 receptor and activity of rheumatic diseases characterised immune system activation
29. Soluble interleukin-2 receptor levels in serum and its relationship to T-cell abnormality and clinical manifestations of disease in patients with systemic lupus erythrematosis
30. Serum levels of soluble forms oft cell activation antigens CD27 and CD25 in systemic lupus erythromatosis in relation to lymphocyte count and disease course
31. Expression of IL-2R, IL-4R, IL-6R on peripheral blood lymphocytes in systemic lupus erythromatosis and correlation with disease activity: A prospective study
32. Serum interleukin-2 receptor in rheumatoid arthritis: A prognostic indicator of disease activity?
33. Elevated soluble interleukin-2 receptor levels in the sera and synovial of with patients with rheumatoid arthritis
34. Serum concentrations of soluble interleukin-2 receptor in patients with rheumatoid arthritis: Effect of second line drugs
35. Serial measurements of serum interleukin-2 receptor levels in patients with rheumatoid arthritis: Limited evidence for a role of T cell activation in clinical exacerbations
36. Serum interleukin-2receptor for the early diagnosis of rheumatoid arthritis
37. Cytokine levels in serum and synovial fluid of patients with juvenile rheumatoid arthritis
38. Soluble interleukin-2 receptor in primary and secondary Sjogren's syndrome
39. Pleural fluid soluble interleukin 2 receptor in rheumatoid arthritis and system lupus erythromatosis
40. Immunopathology of experimental autoimmune uveoretinitis in primates
41. Treatment of noninfectious immediate and posterior uveitis with the humanized anti-Tac mAb: A phase I/II clinical trial
42. The soluble interleukin-2 receptor: Biologs, function and clinical application
43. A review of interleukin-2 antagonists in solid organ transplantation
44. Daclizumab: A review of its use in the prevention of acute rejection in renal transplant patients
45. A phase I trial of humanized anti-interleukin-2 receptor antibody in renal transplantation
46. Interleukin-2-receptor blockade with dacluzimab to prevent acute rejection in renal transplantation
47. Reduction of acute renal allograft rejection by daclizumab
48. Anti-Tac-H, a humanized antibody to the interleukin-2 receptor, prolongs primate cardiac allograft survival
49. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody
50. Phase II clinical trial with daclizumab for prevention of acute rejection in liver transplant patients
51. Experience with daclizumab in liver transplantation
52. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation
53. Graft-versus-host disease
54. Graft-versus-host disease
55. Perspectives in the prevention and treatment of acute graft versus host disease
56. Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukaemic marrow transplant recipients
57. The immunopathophysiology of acute graft-versus-host-disease
58. The cytokine modulation of acute graft-versus-host disease
59. Soluble interleukin 2 receptors in patients after bone marrow transplantation
60. The role of alloreactive cytotoxic and lymphokine-secreting T lymphocytes in the development of acute graft-versus-host disease
61. Clinical relevance of serum soluble interleukin-2 receptor levels in acute and chronic graft-versus-host disease
62. Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease
63. Soluble interleukin-2 receptor serum levels after allogeneic bone marrow transplantation as a marker of GVHD
64. Monitoring soluble interleukin-2 receptor levels in related and unrelated donor allogeneic bone marrow transplantation
65. Effects on in-vivo administration of a monoclonal antibody specific for the interleukin-2 receptor on the acute graft-versus-host reaction in mice
66. Prophylaxis of graft-versus-host disease in identical sibling donor bone marrow transplant by anti-IL-2 receptor monoclonal antibody LO-Tact-1
67. Prevention of graft-versus-host disease (GvHD) by elimination of recipient-reactive donor T-cells with recombinant toxins that target the interleukin-2 (IL-2) receptor
68. Treatment of acute graft-versus-host disease with humanized anti-Tac: An antibody that binds to the interleukin-2 receptor
69. Dacluzimab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease
70. Interleukin receptors in lymphoid lesions: Relevance to diagnosis, biology, and therapy
71. Adult T-cell leukemia: Clinical and hematologic features of 16 cases
72. Characterization and distribution of nucleic acid sequences of a novel type C retrovirus isolated from neoplastic human T lymphocytes
73. HTLV-I and HTLV-II world-wide distribution: Reanalysis of 4,832 immunoblot results
74. Human T cell leukemia virus type I (HTLV-I) and human diseases
75. Effect of human T-lymphotropic virus type I infection on non-Hodgkin's lymphoma incidence
76. Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell leukemia/ymphoma virus negative Sezary leukemia, and their distinction using anti-Tac
77. Major prognostic factors of adult patients with advanced T-cell lymphoma/leukemia
78. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine
79. Zidovudine and interferon therapy for adult T-cell leukaemia/lymphoma. Results of a preliminary study at UHWI-Mona
80. The interleukin-2 receptor: A target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia
81. Radioimmunotherapy of interleukin2α-expressing adult T-cell leukemia with Yttrium-90-labelled anti-Tac
82. Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required forthe delivery of fragment A to the cytosol of target cells
83. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell
84. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides
85. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies